T

Creador Agave Spirits Introduces Its Second Release with Six Expressions

Retrieved on: 
Wednesday, November 8, 2023
Sola, San Francisco World Spirits Competition, Agave angustifolia, Herbal, Vodka, Agave, Cooking, Clay, Fermentation, Glass, Gypsophila, Tobacco, Chocolate, Distillation, Creador, Honey, Partnership, Restaurant, Love, Hand, Lumbres, Candy, Drink, Piqa, El Horno Creek, T, Nose, Liquor, Fashion design, Wine, Sierra Sur de Oaxaca

AUSTIN, Texas, Nov. 8, 2023 /PRNewswire-PRWeb/ -- Creador Agave Spirits, renowned for its unparalleled agave distillates, is introducing its second release of destilado de 100% agave. Each of the six new expressions is milled by hand, clay pot fermented and distilled by maestro palenquero JosI Alberto Pablo in San Bernardo Mixtepec, Oaxaca. Creador is committed to the work of the mezcaleros, and guided by principles of humility, respect, collaboration, craft, and transparency.

Key Points: 
  • AUSTIN, Texas, Nov. 8, 2023 /PRNewswire-PRWeb/ -- Creador Agave Spirits , renowned for its unparalleled agave distillates, is introducing its second release of destilado de 100% agave.
  • "Our first and second releases of destilado are produced in Oaxaca by maestro palenquero JosI Alberto Pablo," says Marcus PiQa, founder of Creador Agave Spirits.
  • Creador Agave Spirits offer ancestral-style agave spirits top-shelf clay pot distilled 100% agave spirits distilled in Oaxaca that honor the work of mezcal makers.
  • The second release of Creador Agave Spirits is made using traditional methods.

An invitation from the Department for Education & Nash Squared

Retrieved on: 
Friday, September 15, 2023
Curriculum, Partnership, Student, City, Department for Education, T, Software design, Noble Street College Prep, Square, Creative industries, Nursing

LONDON, Sept. 15, 2023 /PRNewswire/ -- Register here

Key Points: 
  • Nash Squared is excited to announce a new partnership with the Department for Education to support our mission to build the UK's tech talent pipeline.
  • The three most desired skillsets within tech are cybersecurity experts, big data analysts, and technical architects, meaning the competition for talent is higher than ever.
  • That is why we are proud to be working with the Department for Education on T Levels – the next level qualification designed to catapult young people into the careers of tomorrow.
  • Nash Squared has been part of an influential group of employers involved in the development of the curriculum for the cyber security T Level pathway.

XNK Therapeutics to present at the 8th CAR-TCR Summit in Boston

Retrieved on: 
Monday, August 28, 2023
Linda, NKT, T, NK, TIL, QA, Pharmaceutical industry

HUDDINGE, Sweden, Aug. 28, 2023 /PRNewswire/ -- The annual CAR-TCR Summit is the world's pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types (αβ T, γδ T, NK, NKT, Macrophage, TIL and more), Over 1000 experts from both pharmaceutical companies, including autologous and allogeneic cell therapy drug developers, and academia participate to advance the field.

Key Points: 
  • XNK Therapeutics AB ("XNK") today announced that Linda Brick, Head of QA, will be speaking at the 8th CAR-TCR Summit in Boston.
  • HUDDINGE, Sweden, Aug. 28, 2023 /PRNewswire/ -- The annual CAR-TCR Summit is the world's pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types (αβ T, γδ T, NK, NKT, Macrophage, TIL and more), Over 1000 experts from both pharmaceutical companies, including autologous and allogeneic cell therapy drug developers, and academia participate to advance the field.
  • On August 30, Linda Brink will present XNK and talk about improving training and internal collaboration initiatives to address the demand for skilled workers in cell therapy manufacturing.

XNK Therapeutics to present at the 8th CAR-TCR Summit in Boston

Retrieved on: 
Monday, August 28, 2023
Linda, NKT, T, NK, TIL, QA, Pharmaceutical industry

HUDDINGE, Sweden, Aug. 28, 2023 /PRNewswire/ -- The annual CAR-TCR Summit is the world's pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types (αβ T, γδ T, NK, NKT, Macrophage, TIL and more), Over 1000 experts from both pharmaceutical companies, including autologous and allogeneic cell therapy drug developers, and academia participate to advance the field.

Key Points: 
  • XNK Therapeutics AB ("XNK") today announced that Linda Brick, Head of QA, will be speaking at the 8th CAR-TCR Summit in Boston.
  • HUDDINGE, Sweden, Aug. 28, 2023 /PRNewswire/ -- The annual CAR-TCR Summit is the world's pre-eminent industry-leading comprehensive forum that unites the global cell therapy community across a variety of cell types (αβ T, γδ T, NK, NKT, Macrophage, TIL and more), Over 1000 experts from both pharmaceutical companies, including autologous and allogeneic cell therapy drug developers, and academia participate to advance the field.
  • On August 30, Linda Brink will present XNK and talk about improving training and internal collaboration initiatives to address the demand for skilled workers in cell therapy manufacturing.

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Retrieved on: 
Tuesday, August 1, 2023
GMP, China National Intellectual Property Administration, Patent, Antigen, CNIPA, Partnership, IPSC, NKT, STAR, National University Hospital, Clinical trial, Cell, Immunotherapy, CN, NUH, Agency for Science, Technology and Research, Hematological Cancer Research Investment and Education Act, Biological patents in the United States, Risk, A*STAR, Cytomics, Blood, Agency, Cancer, Same, Outline of health sciences, Health Sciences Authority, T, HSA, NKG2D, Pharmaceutical industry, Vaccine, Science, Research

SINGAPORE, Aug. 1, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, which is exclusively licensed from the Agency for Science, Technology and Research (A*STAR), has been granted a patent by the China National Intellectual Property Administration (CNIPA).

Key Points: 
  • The Company holds an exclusive, worldwide license, for use in immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • CytoMed's CAR-γδ T cell technology has been developed as an investigational cancer therapy to target NKG2D ligands, a type of stress-induced cancer antigens.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive a novel synthetic γδ NKT cells for the treatment of various types of cancers.
  • A patent for this proprietary technology has already been granted in Japan, and this asset is under preclinical development.

Strong Tower Consulting Highlights the Potential of AI at Disability:IN Global Conference

Retrieved on: 
Wednesday, July 19, 2023
Consulting, Data Management, Technology, People with Disabilities, Professional Services, Small Business, DEI (Diversity, Equity and Inclusion), Artificial Intelligence, Other Professional Services, Consumer, Human Resources, Virtue, Workforce, DOBES, OpenAI, Growth, ChatGPT, Croswell, Disability, Intelligence, T, Conference, Insurance

Strong T ower Consulting , a Washington-based management-consulting firm recently attended and presented at the Disability:IN Global Conference, the corporate disability inclusion event of the year, held July 10-14 in Orlando.

Key Points: 
  • Strong T ower Consulting , a Washington-based management-consulting firm recently attended and presented at the Disability:IN Global Conference, the corporate disability inclusion event of the year, held July 10-14 in Orlando.
  • Strong Tower Partner John Croswell was a featured speaker during the conference, highlighting the growth of disability-owned business enterprises (DOBE) and the potential of artificial intelligence in aiding individuals with disabilities.
  • The Disability:IN Global Conference is renowned as the largest event of its kind, uniting business leaders, industry experts, advocates, and individuals with disabilities to advance disability inclusion in the workforce and marketplace.
  • More information about the Disability:IN Global Conference and to access valuable resources on disability inclusion is available at: disabilityin.org/2023conference .

Genedata Announces Partnership with Dragonfly Therapeutics to Support Novel Immune Engager R&D

Retrieved on: 
Thursday, July 13, 2023
Molecular biology, Therapy, Workflow, Cancer, Dragonfly, Cell, RNA, Patient, Engineering, Research, T, Technology transfer, D, Fine chemical, IND

BASEL, Switzerland, July 13, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Dragonfly Therapeutics, a clinical-stage biotechnology company developing novel immunotherapies, is using the Genedata Biologics® integrated R&D workflow platform. The platform supports Dragonfly's development of novel multi-specific therapies designed as natural combinations harnessing NK cells, γδ T cells, CD8+ T cells, and other cells of the innate and adaptive immune system, to provide a unique therapeutic window beyond current therapies for treatment of cancer and chronic inflammatory diseases.

Key Points: 
  • BASEL, Switzerland, July 13, 2023 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Dragonfly Therapeutics, a clinical-stage biotechnology company developing novel immunotherapies, is using the Genedata Biologics ® integrated R&D workflow platform.
  • "We selected Genedata Biologics because of its unique workflow and registration engine that supports processes from candidate selection all the way through IND filings and commercialization," said Ann Cheung, Ph.D., Head of Research at Dragonfly Therapeutics.
  • "It was important to us to put workflows in place that can give us out-of-the-box support for our novel R&D programs.
  • "By providing Dragonfly Therapeutics with a central data backbone for their discovery pipeline, we are making their R&D faster and more efficient," said Othmar Pfannes, Ph.D., CEO of Genedata.

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US

Retrieved on: 
Thursday, July 6, 2023
Yee, Patent, Antigen, Cytomics, IPSC, NKT, STAR, National University Hospital, Alberta Enterprise Group, United States patent law, Innovation, Research, Immunotherapy, NUH, Assistant, CAR, Cancer, Hematological Cancer Research Investment and Education Act, Gamma delta T cell, Biological patents in the United States, Patient, Risk, A*STAR, Same, Outline of health sciences, Health Sciences Authority, Therapy, T, HSA, NKG2D, Vaccine

Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.

Key Points: 
  • Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.
  • CytoMed holds an exclusive, worldwide license, for use on immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive γδ NKT cells for cancer treatments.
  • A patent for this proprietary technology has already been granted in Japan and this asset is under preclinical development.

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
CRC, Clinical trial, Maxima and minima, HER2, Nanakaly Hospital for Hematology & Oncology, Neoplasm, Trinket, Metastatic breast cancer, RECIST, Dragonfly, NK, Toxicity, NSCLC, Index, ASCO, Medical director, Patient, MBC, Cancer, Colorectal cancer, Infrared spectroscopy correlation table, Therapy, T, Safety, Nivolumab, Pharmaceutical industry, Medical imaging

WALTHAM, Mass., June 5, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago. The presentation, given by lead investigator Dr. Howard P. Safran, Chief of Hematology/Oncology at the Lifespan Cancer Institute and Medical Director for the Brown University Oncology Group, describes Dragonfly's Phase 1/2 clinical trial of its DF1001 HER2-targeting TriNKET®, a first-in-human study exploring the safety, tolerability, and preliminary biological and clinical activity of DF1001.

Key Points: 
  • WALTHAM, Mass., June 5, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago.
  • Single agent activity was seen in both HER2 high and HER2 low patients who previously progressed on prior HER2 directed therapies."
  • As of the April 14th data cutoff for ASCO presentation, Dragonfly has treated 106 patients with DF1001 monotherapy.
  • There are six Dragonfly developed drugs in the clinic – including DF1001.

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results at ASCO 2023 Annual Meeting

Retrieved on: 
Monday, June 5, 2023
CRC, Clinical trial, Maxima and minima, HER2, Nanakaly Hospital for Hematology & Oncology, Neoplasm, Trinket, Metastatic breast cancer, RECIST, Dragonfly, NK, Toxicity, NSCLC, Index, ASCO, Medical director, Patient, MBC, Cancer, Colorectal cancer, Infrared spectroscopy correlation table, Therapy, T, Safety, Nivolumab, Pharmaceutical industry, Medical imaging

WALTHAM, Mass., June 5, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago. The presentation, given by lead investigator Dr. Howard P. Safran, Chief of Hematology/Oncology at the Lifespan Cancer Institute and Medical Director for the Brown University Oncology Group, describes Dragonfly's Phase 1/2 clinical trial of its DF1001 HER2-targeting TriNKET®, a first-in-human study exploring the safety, tolerability, and preliminary biological and clinical activity of DF1001.

Key Points: 
  • WALTHAM, Mass., June 5, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of its DF1001 TriNKET immune engager clinical data at the ASCO 2023 Annual Meeting in Chicago.
  • Single agent activity was seen in both HER2 high and HER2 low patients who previously progressed on prior HER2 directed therapies."
  • As of the April 14th data cutoff for ASCO presentation, Dragonfly has treated 106 patients with DF1001 monotherapy.
  • There are six Dragonfly developed drugs in the clinic – including DF1001.